Edgewise Shares Rise Premarket on FDA Fast-Track Designation
By Colin Kellaher
Edgewise Therapeutics shares moved higher in premarket trading Tuesday after the clinical-stage biopharmaceutical company won U.S. Food and Drug Administration fast-track designation for EDG-5506 for the treatment of Duchenne muscular dystrophy.
Shares, which closed Monday at $18.95, were recently up 7.9% to $20.45 in premarket trading.
The Boulder, Colo., company on Tuesday said it is currently conducting a pair of Phase 2 placebo-controlled studies of EDG-5506 in Duchenne, a severe, degenerative muscle disorder.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
The FDA previously granted orphan-drug designation to EDG-5506 for the treatment of Duchenne and Becker muscular dystrophy, rare-pediatric-disease designation for the treatment of Duchenne, and fast-track designation for the treatment of Becker.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2024 08:49 ET (13:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks